LONDON, U.K. AND PLANO, TX, U.S. (19 May 2022) – Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that three additional US patents have recently issued, increasing the number of issued and pending patent applications the Company owns or exclusively licenses to thirty.
The technology covered by the patents, includes:
- Extracorporeal membrane oxygenation (ECMO) innovations for when people who are very ill with conditions of the heart and lungs, or who are waiting for or recovering from a heart transplant, require a portable artificial lung;
- Continuous Positive Airway Pressure (CPAP) innovations, a type of non-invasive ventilation (NIV) or breathing support, and;
- Consumer replaceable molecular sieve technology, used to remove Nitrogen from ordinary air to produce medical grade supplemental oxygen.
Robert Rauker, CEO of Belluscura plc, said, “Our pioneering engineering team continues to develop next generation oxygen enrichment technology along with our research partner, Separation Design Group. We see significant expanding future opportunities in the supplemental oxygen field.”
For further information please contact:
Belluscura plc www.belluscura.com
Robert Rauker, Chief Executive Officer via Walbrook PR
Anthony Dyer, Chief Financial Officer
SPARK Advisory Partners Limited (NOMAD)
Tel: +44 (0)20 3368 3550
Neil Baldwin
Dowgate Capital Limited (Broker)
Tel: +44 (0)20 3903 7715
James Serjeant / Nicholas Chambers
Walbrook PR Ltd (Media & Investor Relations)
Tel: +44 (0)20 7933 8780 or belluscura@walbrookpr.com
Paul McManus / Sam Allen Mob:
+44 (0)7980 541 893 / +44 (0)7502 558 258
About Belluscura plc
Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.
